Security key
35104E100
4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT)
CUSIP: 35104E100
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 39,480,388
- Total 13F value
- $343,063,699
- Share change
- -867,099
- Put/Call ratio
- 18%
- SEC-reported price per share
- $8.69
- Number of holders
- 129
- Value change
- -$4,201,365
- Number of buys
- 60
- Number of sells
- 66
- Shares outstanding
- 51,571,939
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q3 2025
Institutions
129
Top holders
10
FDMT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
4D Molecular Therapeutics, Inc. SEC filings
4D Molecular Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 35104E100
Recent filing periods:
Ownership snapshot
Top reported holders of FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
3/4/5
Lead comparable stake: 6.6%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 6.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
BlackRock, Inc.
6.6%
Venrock Healthcare Capital Partne...
1.5%
Deep Track Capital, LP
1.3%
BVF INC/IL
9%
RA CAPITAL MANAGEMENT, L.P.
8.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
6.6%
|
$26,613,959
3,062,596 shares
|
-$4,803,137 | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
1.5%
|
$2,202,200
677,600 shares
|
-$7,393,006 | 31 Mar 2025 |
| Deep Track Capital, LP |
13D/G
|
1.3%
|
$1,982,175
609,900 shares
|
$0 | 31 Dec 2024 |
| BVF INC/IL |
13F
Company
|
9%
|
$17,174,662
4,629,289 shares
|
— | 30 Jun 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
13F
10%+ Owner · Company
|
8.8%
from 13F
|
$74,517,236
8,173,211 shares
mixed-class rows
|
— | 09 Dec 2024 |
| GOLDMAN SACHS GROUP INC |
13F
Company
|
8.1%
|
$15,430,869
4,159,264 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
129
Shares
39,480,388
Rows available
129
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
117
Q3 2025 holders
129
Holder diff
12
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend